Group 1 - The company plans to issue shares to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group Co., Ltd. from 38 counterparties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1] - The company intends to raise supporting funds by issuing shares to no more than 35 qualified specific objects as part of the transaction [1] - The announcement includes a revised draft of the "Report on Issuing Shares to Purchase Assets and Raising Supporting Funds and Related Transactions" [1] Group 2 - The revised report updates the stock issuance price and quantity for the asset purchase, as well as the raised supporting funds [2] - The decision-making process and approval status of the transaction have been updated in the report [2] - The financial status and profitability analysis of the target company have been improved and updated in the management discussion and analysis section [2]
科源制药: 关于发行股份购买资产暨关联交易报告书（草案）修订说明的公告